Filtered library · Theme

oncology-tce-platforms theme · 1 dossier

Dossiers in the oncology-tce-platforms theme cluster — 1 name moving on shared catalysts.

VIR

Post-COVID biotech pivot — VIR-5500 Phase 1 (PSMA dual-masked TCE) first patient dosed 2026-04-13; AACR 2026-04-25→30 posters and Q1 2026 earnings (~early May) are the next binary inflections. DORMANT until first-cohort safety disclosure…

a5Earnings inflection rare-disease-approvals t-cell-engagers

catalyst · 2026-04-25 →